Pain, Menstrual
Conditions
Brief summary
This study evaluates the effects of rocuronium injection pain to menstrual cycle phases.Half of participants will receive follicular phase, while the other half will receive luteal phase.
Detailed description
Menstrual period includes a spectrum of emotional and somatic symptoms observed in luteal phase of menstrual cycle, which are disappeared after menstruation. During menstrual cycle, fluctuation in sexual hormones results in attitude change and alteration in pain perception. Different studies reported some interactions between sex hormones and central nervous system, which might be linked to activity of serotonin and beta-endorphin in the brain. Pain perception differs during menstrual cycle. It has been recommended that estrogens might have an influence on somatic sensory process. Some studies reported a significant effect of pain sensitivity with higher levels of progesterone and some other studies reported similar patterns for pain perception. There are reports of more complaint of pain in luteal phase of menstruation, which is suggested as the reason for functional changes in women during menstrual cycle.
Interventions
DRUGRocuronium 0,6mg/kg
patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
Sponsors
Aydin Adnan Menderes University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* American Society of Anesthesiology Classification (ASA) I-II * 18-45 years * Regular menstrual cycle
Exclusion criteria
* Irregular menstrual cycles * Patients receiving hormones or drugs affecting the ovulatory cycle * Amenorrhea * Pregnancy * Climacteric patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain measure | 10 second | Tracheal intubating dose of 0.6 mg/kg of rocuronium at room temperature was injected over 10 -15 s. The patients were observed immediately if they had pain in the arm, and the response was assessed. Withdrawal movements were also assessed and scored as follows: no movements = 0, movement limited to hand = 1, movement limited to the forearm including the elbow joint = 2, and movement of the upper arm including the shoulder joint = 3 |
Countries
Turkey (Türkiye)
Outcome results
None listed